Search

everythinglearnresearchcommunity

for

Search:↓

Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Indinavir can cause hair loss and other skin problems.

Using Favipiravir, a COVID-19 treatment drug, likely doesn't cause hair loss.

Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.

Indinavir therapy can cause reversible skin, hair, and nail darkening.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

ART for HIV/AIDS can cause side effects but is crucial for managing the infection.

Indinavir, especially with vitamin A, may cause bone changes, but switching to nelfinavir can reduce these effects.

Eclipta alba leaf alkaloids may help treat HIV by inhibiting the virus's activity.

Peginterferon alpha-2a effectively treats acute hepatitis C in hemodialysed patients, despite some side effects.

A woman's total hair loss from hepatitis C treatment grew back after stopping the medication.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.

Research on HIV-1 capsid inhibitors has progressed significantly, with the U.S. leading in contributions.

A man lost all his hair permanently after hepatitis C treatment, a side effect not seen before.

Older age, pre-existing skin conditions, cirrhosis, and pegylated interferon use increase the risk of skin issues during hepatitis C treatment.

Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.

Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.

A man with HIV developed skin and hair issues after starting HIV treatment, which improved with topical treatment.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

A woman with HIV had a severe skin condition that improved with antiretroviral therapy.

CTP-543 is generally safe for treating alopecia areata.

Some HIV treatments can harm mitochondria, potentially causing side effects like lactic acidosis and nerve damage.

Cepharanthine and Trifluoperazine are effective against SARS-CoV-2.

Six African American women experienced hair loss after switching to a new HIV medication.

Some patients may experience temporary total hair loss from hepatitis C treatment with PEG-interferon and ribavirin.